A Qualitative Evaluation of the Australian Community Pharmacy Agreement

Author:

Jackson John K.1,Chaar Betty B.2ORCID,Kirkpatrick Carl M.1,Scahill Shane L.3ORCID,Mintrom Michael4ORCID

Affiliation:

1. Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

2. School of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia

3. School of Pharmacy, University of Auckland, Auckland 1023, New Zealand

4. School of Social Sciences, Faculty of Arts, Monash University, Melbourne, VIC 3800, Australia

Abstract

The Australian Federal Government’s Community Pharmacy Agreement (Agreement), initiated in 1990 and renegotiated every five years with a pharmacy owners’ organisation, is the dominant policy directing community pharmacy. We studied the experience with the Agreements of 38 purposively selected individual pharmacists and others of diverse backgrounds, using in-depth, semi-structured interviews. Although perceived to lack transparency in negotiation and operation, as well as paucity of outcome measures, the Agreements have generally supported the viability of community pharmacies and on balance, contributed positively to the public’s access to medicines. There were, however, contradictory opinions regarding the impact of the policy’s regulation of pharmacy locations, including the suggestion that they provide existing owners with an undue commercial advantage. A reported shortcoming of the Agreements was their impact on pharmacists’ abilities to expand their scopes of practice and assist patients to make better use of medicines, in part due to the funding being almost totally focused on supply-related functions. The support for programs such as medication management services was perceived to be limited, and opportunities for diversification in pharmacy practice appeared constrained. Future pharmacy policy developed by the government could be more inclusive of a diverse range of stakeholders, seek to better utilise pharmacists’ expertise, and have a greater focus on health outcomes.

Publisher

MDPI AG

Subject

Microbiology (medical),Immunology,Immunology and Allergy

Reference71 articles.

1. Low, J., Hattingh, L., and Forrester, K. (2013). Australian Pharmacy Law and Practice, Elsevier. [2nd ed.].

2. Nissen, L., and Singleton, J. (2023, October 09). Explainer: What is the Community Pharmacy Agreement? The Conversation. Available online: https://theconversation.com/explainer-what-is-the-community-pharmacy-agreement-38789.

3. Community pharmacy in Australia;Benrimoj;Aust. Health Rev.,2004

4. PBS Analytics and Strategic Insight Section, Pricing and PBS Policy Branch, Technology Assessment and Access Division (2023, October 09). The PBS Expenditure and Prescriptions Report 1 July 2021–30 June 2022. Department of Health and Aged Care, Available online: https://www.pbs.gov.au/statistics/expenditure-prescriptions/2021-2022/PBS-Expenditure-and-Prescriptions-Report-1-July-2021-to-30-June-2022.PDF.

5. Department of Health and Aged Care (2023, October 09). Community Pharmacy Agreements. The Pharmaceutical Benefits Scheme, Available online: https://www.pbs.gov.au/info/general/sixth-cpa-pages/previous-community-pharmacy-agreements.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3